ReviewApoptosis : an international journal on programmed cell death2025
A new perspective on iron-dependent cell death: PRDX-1-mediated ferroptosis in tumor cells.
Review in Apoptosis : an international journal on programmed cell death, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Effects of Isorhapontigenin on Cell Viability, Colony-Forming Efficiency, and Ferroptosis via Methyltransferase-Like 14-Mediated mMolecular carcinogenesis · 2026Article
- Targeting ferroptosis in osteoporosis: mechanisms and natural products therapies.Frontiers in pharmacology · 2026Review
- PRDX1 promotes clear cell renal cell carcinoma progression by modulating EGFR-dependent AKT pathway activation.Frontiers in pharmacology · 2026Article
- Evaluation of anemia and iron status in Japanese patients with gynecological malignancy: retrospective cohort studyBMC women's health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Ferroptosis is a novel regulated cell death characterized by excessive membrane lipid peroxidation in an iron- and ROS-dependent manner, which is increasingly recognized for its role in tumor suppression and overcoming therapy resistance in various cancers. Induction of ferroptosis has been shown to sensitize cancer cells to chemotherapy, targeted therapy, and immunotherapy, thereby providing a novel strategy to tumor therapy. Peroxiredoxin 1 (PRDX1), an antioxidant enzyme, regulates redox homeostasis and is involved in tumor invasion, metastasis and prognosis. Increasing evidence suggests that PRDX1 is a negative regulator of ferroptotic cell death. Hence, regulating ferroptosis, via targeting PRDX1 and regulating PRDX1' function, holds promise for the treatment of tumors. In this review, we comprehensively summarized the regulatory of PRDX1 on ferroptosis and discussed the potential of PRDX1-mediated ferroptosis on tumor therapy, aiming to provide a distinct method for finding potential targets to enhance the effectiveness of ferroptosis-based tumor treament.
Indexed as
Identifiers
40488836What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.